PCOS (Polycystic Ovary Syndrome) — RepurpOS

Disease overview

Alterations

116

Molecular (A)

100

Clinical (B–E)

Direct drugs

112

Via biomarker

Natural agents

Natural products

111

Merged ranked

177

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, PubMed NP, ClinicalTrials.gov NP · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission

PCOS is a lifelong endocrine disorder; complete spontaneous resolution rare; some phenotypic improvement with menopause; fertility returns in 50-70% with ovulation induction; metabolic features persist

Best-intervention remission

Weight loss of 5-10% restores ovulation in 55-90% of anovulatory PCOS women; metformin restores ovulation in 30-50%; letrozole (ovulation induction): 27% live birth rate per cycle (PPCOS II); lifestyle modification: 50-80% improvement in menstrual regularity

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Large — lifestyle modification and metformin are evidence-based first-line but most patients receive OCPs (treating symptoms only, not the underlying metabolic disorder)

Primary barrier

framing/practice

Barrier detail: OCP (oral contraceptive pill) is most commonly prescribed for PCOS, treating symptoms (irregular periods, hirsutism) without addressing the underlying insulin resistance and metabolic risk; OCP does not treat infertility and may worsen insulin sensitivity; the PCOS field has lacked a clear pharmacotherapy standard

Last SoC change: 2023 — International PCOS Guideline updated; letrozole formally recommended over clomiphene for ovulation induction; metformin recommended as first-line metabolic treatment; GLP-1 agonists emerging as adjunct; spironolactone for hyperandrogenism; first guidelines were 2011 (Endocrine Society)

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0008487 · ORPHA: ORPHA:95699

Right to Try Relevance

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Polycystic Ovary Syndrome may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

103

Phase 3: 34, Phase 2: 55, Phase 1: 14

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

116

Actionable

Pipeline Compounds (Top 6)

Darapladib, Fenretinide, Acetylcysteine, Bromocriptine, Calcium, Cetrorelix

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

116 total · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abnormality of metabolism/homeostasis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Amenorrhea	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Enlarged polycystic ovaries	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hirsutism	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Obesity	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Oligomenorrhea	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ADCY5 adenylate cyclase 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ANKRD66 ankyrin repeat domain 66	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AOPEP aminopeptidase O (putative)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARL14EP ARF like GTPase 14 effector protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BMPR1B bone morphogenetic protein receptor type 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Blood pressure	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Body Weight	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Body mass index (BMI)	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
CADPS calcium dependent secretion activator	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDH10 cadherin 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHEK2 checkpoint kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COXFA4 cytochrome c oxidase associated subunit FA4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COXFA4L2 cytochrome c oxidase hypoxia associated subunit FA4L2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP19A1 cytochrome P450 family 19 subfamily A member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Clinical Pregnancy rate	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
DENND1A DENN domain containing 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DRC11 dynein regulatory complex subunit 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DRD2 dopamine receptor D2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EMID1 EMI domain containing 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERBB4 erb-b2 receptor tyrosine kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ESR1 estrogen receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FER1L6 fer-1 like family member 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FSHB follicle stimulating hormone subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FSHR follicle stimulating hormone receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FTO FTO alpha-ketoglutarate dependent dioxygenase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Free Androgen Index	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
GATA4 GATA binding protein 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GLP1R glucagon like peptide 1 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GNAI1 G protein subunit alpha i1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GNRHR gonadotropin releasing hormone receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GPD2 glycerol-3-phosphate dehydrogenase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HMGA2 high mobility group AT-hook 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IRF1 interferon regulatory factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KCNS2 potassium voltage-gated channel modifier subfamily S member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KLF13 KLF transcription factor 13	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LHCGR luteinizing hormone/choriogonadotropin receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LZTS3 leucine zipper tumor suppressor family member 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MINAR2 membrane integral NOTCH2 associated receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MSH6 mutS homolog 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND1 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND2 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND3 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND4 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND4L mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND5 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND6 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA1 NADH:ubiquinone oxidoreductase subunit A1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA10 NADH:ubiquinone oxidoreductase subunit A10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA11 NADH:ubiquinone oxidoreductase subunit A11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA12 NADH:ubiquinone oxidoreductase subunit A12	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA13 NADH:ubiquinone oxidoreductase subunit A13	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA2 NADH:ubiquinone oxidoreductase subunit A2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA3 NADH:ubiquinone oxidoreductase subunit A3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA5 NADH:ubiquinone oxidoreductase subunit A5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA6 NADH:ubiquinone oxidoreductase subunit A6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA7 NADH:ubiquinone oxidoreductase subunit A7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA8 NADH:ubiquinone oxidoreductase subunit A8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA9 NADH:ubiquinone oxidoreductase subunit A9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAB1 NADH:ubiquinone oxidoreductase subunit AB1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF1 NADH:ubiquinone oxidoreductase complex assembly factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF2 NADH:ubiquinone oxidoreductase complex assembly factor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF3 NADH:ubiquinone oxidoreductase complex assembly factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF4 NADH:ubiquinone oxidoreductase complex assembly factor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB1 NADH:ubiquinone oxidoreductase subunit B1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB10 NADH:ubiquinone oxidoreductase subunit B10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB11 NADH:ubiquinone oxidoreductase subunit B11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB2 NADH:ubiquinone oxidoreductase subunit B2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB3 NADH:ubiquinone oxidoreductase subunit B3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB4 NADH:ubiquinone oxidoreductase subunit B4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB5 NADH:ubiquinone oxidoreductase subunit B5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB6 NADH:ubiquinone oxidoreductase subunit B6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB7 NADH:ubiquinone oxidoreductase subunit B7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB8 NADH:ubiquinone oxidoreductase subunit B8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB9 NADH:ubiquinone oxidoreductase subunit B9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFC1 NADH:ubiquinone oxidoreductase subunit C1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFC2 NADH:ubiquinone oxidoreductase subunit C2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS1 NADH:ubiquinone oxidoreductase core subunit S1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS2 NADH:ubiquinone oxidoreductase core subunit S2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS3 NADH:ubiquinone oxidoreductase core subunit S3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS4 NADH:ubiquinone oxidoreductase subunit S4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS5 NADH:ubiquinone oxidoreductase subunit S5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS6 NADH:ubiquinone oxidoreductase subunit S6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS7 NADH:ubiquinone oxidoreductase core subunit S7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS8 NADH:ubiquinone oxidoreductase core subunit S8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV1 NADH:ubiquinone oxidoreductase core subunit V1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV2 NADH:ubiquinone oxidoreductase core subunit V2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV3 NADH:ubiquinone oxidoreductase subunit V3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NEIL2 nei like DNA glycosylase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NR3C2 nuclear receptor subfamily 3 group C member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PGR progesterone receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PPARG peroxisome proliferator activated receptor gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PROX1 prospero homeobox 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RNF43 ring finger protein 43	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ROCK1 Rho associated coiled-coil containing protein kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC5A2 solute carrier family 5 member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SUOX sulfite oxidase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Serum follicle stimulating hormone (FSH) level	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Serum luteinizing hormone (LH) level	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
THADA THADA armadillo repeat containing	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TMEM135 transmembrane protein 135	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TOX3 TOX high mobility group box family member 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TTC28 tetratricopeptide repeat domain 28	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TWIST2 twist family bHLH transcription factor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
VDR vitamin D receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
YAP1 Yes1 associated transcriptional regulator	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ZBTB16 zinc finger and BTB domain containing 16	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ovulation rate	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
pregnancy rate	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
weight loss	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
ABIRATERONE ACETATE		Gene-targeted
ACETAZOLAMIDE	None	Gene-targeted
AMPHETAMINE	None	Gene-targeted
BICALUTAMIDE	None	Gene-targeted
CARBACHOL	None	Gene-targeted
CIPROFLOXACIN	None	Gene-targeted
CLOMIPRAMINE	None	Gene-targeted
DIAZEPAM	None	Gene-targeted
DIBOTERMIN ALFA	agonist	Gene-targeted
DICHLORPHENAMIDE	None	Gene-targeted
DIETHYLSTILBESTROL	None	Gene-targeted
ENZALUTAMIDE		Gene-targeted
EPIRUBICIN	None	Gene-targeted
EPTOTERMIN ALFA	agonist	Gene-targeted
ETHOXZOLAMIDE	None	Gene-targeted
FLUMAZENIL	None	Gene-targeted
GEFITINIB		Gene-targeted
IMIPRAMINE	None	Gene-targeted
INDAPAMIDE	None	Gene-targeted
INDOMETHACIN	None	Gene-targeted
ISOSORBIDE DINITRATE	None	Gene-targeted
MAFENIDE	None	Gene-targeted
MECAMYLAMINE	None	Gene-targeted
METFORMIN HYDROCHLORIDE	inhibitor	Gene-targeted
METHAZOLAMIDE	None	Gene-targeted
METHOXSALEN	None	Gene-targeted
METOPROLOL	None	Gene-targeted
MIANSERIN	None	Gene-targeted
NALIDIXIC ACID	None	Gene-targeted
NICOTINE	None	Gene-targeted
NIRAPARIB		Gene-targeted
NORFLOXACIN	None	Gene-targeted
OFLOXACIN	None	Gene-targeted
OLAPARIB		Gene-targeted
PALBOCICLIB		Gene-targeted
PHENYTOIN	None	Gene-targeted
PRAZOSIN	None	Gene-targeted
PREDNISONE		Gene-targeted
RUCAPARIB		Gene-targeted
SIROLIMUS	None	Gene-targeted
SULBACTAM	None	Gene-targeted
TACROLIMUS ANHYDROUS	None	Gene-targeted
TALAZOPARIB		Gene-targeted
TAZOBACTAM	None	Gene-targeted
TROGLITAZONE	None	Gene-targeted
VEMURAFENIB		Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
BICALUTAMIDE	Small molecule	Approved	Strong	100	2 trials 1 Trial pubs 1 RCT View evidence Registry trials NCT05979389 — Bicalutamide Therapy in Young Women With NAFLD and PCOS (RECRUITING) PHASE1 NCT05647356 — The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2 (UNKNOWN) NA Published literature Clinical trial publication Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial (The Journal of clinical endocrinology and metabolism, 2018) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ABIRATERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	4 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIBOTERMIN ALFA Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ENZALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EPTOTERMIN ALFA Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
GEFITINIB Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	3 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METFORMIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	8 trials 5 Trial pubs 3 RCT View evidence Registry trials NCT02689843 — Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS (COMPLETED) EARLY_PHASE1 NCT01482286 — Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS (TERMINATED) PHASE3 NCT03086005 — Study to Assess the Effect of Metformin Supplementation on IVF Outcome in Patients With Polycystic Ovarian Syndrome. (COMPLETED) PHASE3 NCT02635386 — EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) (COMPLETED) PHASE3 NCT00471523 — Treatment of Anovulatory Infertility in PCOS Patients (COMPLETED) PHASE4 NCT02341703 — Ovulation Induction in Clomiphene Citrate Resistant PCO Women (COMPLETED) EARLY_PHASE1 NCT03259919 — Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study (COMPLETED) PHASE2 NCT07399535 — Clinical Investigation of Herbal Formulation and Its Efficacy in Polycystic Ovarian Syndrome (COMPLETED) PHASE1 Published literature Clinical trial publication Bioequivalence of Related GelShield(Ⓡ) Sustained-release Formulations of Metformin: A Pooled Pharmacokinetic Analysis (Clinical therapeutics, 2024) Clinical trial publication [Efficacy and mechanism of electroacupuncture on insulin resistant polycystic ovary syndrome] (Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2020) Clinical trial publication [Observation on therapeutic effect of polycystic ovary syndrome of damp-phlegm constitution treated with embedding therapy on back-shu points and front-mu points combined with needle-pricking therapy on Sifeng (EX-UE 10)] (Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2014) Clinical trial publication Effect of metformin on the level of anti-Mullerian hormone in therapy of polycystic ovary syndrome in obese women (Minerva ginecologica, 2014) Clinical trial publication Effect of metformin hydrochloride in correcting hyperinsulinemia and high leptin levels in treatment of infertile polycystic patients (Journal of Ayub Medical College, Abbottabad : JAMC, 2013) CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NICOTINE Repurposing	Small molecule	Approved	Strong	95	4 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NIRAPARIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NORFLOXACIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
OFLOXACIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
OLAPARIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PALBOCICLIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PHENYTOIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
PREDNISONE Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
RUCAPARIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
SIROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SULBACTAM Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TALAZOPARIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
TAZOBACTAM Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VEMURAFENIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ACETYLCYSTEINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BROMOCRIPTINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CALCIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CETRORELIX	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CETRORELIX ACETATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CINNAMON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CORIFOLLITROPIN ALFA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DAPAGLIFLOZIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DESOGESTREL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DROSPIRENONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ETHINYL ESTRADIOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EXENATIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOLLITROPIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOLLITROPIN BETA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GONADORELIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GONADORELIN ACETATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INOSITOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LETROZOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEVONORGESTREL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LIPOIC ACID, ALPHA	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LIRAGLUTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MARVELON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MEDROXYPROGESTERONE ACETATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MENOTROPINS	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PHENTERMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SAXAGLIPTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SEMAGLUTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIMVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TOPIRAMATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARAPLADIB Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
ACETYLCARNITINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANAKINRA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARGININE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARTENIMOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CABERGOLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CARNITINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHIGLITAZAR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHORIOGONADOTROPIN ALFA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CYPROTERONE ACETATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIENOGEST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ELAGOLIX	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMPAGLIFLOZIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUTAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GONADOTROPIN, CHORIONIC	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IBUPROFEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEVOCARNITINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LICOGLIFLOZIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METFORMIN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OLIVE OIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ORLISTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OXYTOCIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAVINETANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PENTOXIFYLLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PROGESTERONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QUERCETIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RESVERATROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SALSALATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SITAGLIPTIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SPIRONOLACTONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
THYMOQUINONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TILDACERFONT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UBIDECARENONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VILDAGLIPTIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VITAMIN E	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHEMBL:CHEMBL401844 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
FD6 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
NKY80 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ALPRENOLOL Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ASTAXANTHIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CANAGLIFLOZIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DYDROGESTERONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ESTRADIOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ESTRADIOL VALERATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FISH OIL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FOLIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GANIRELIX	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GESTODENE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ICOSAPENT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ISOSORBIDE MONONITRATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MAZDUTIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NOMEGESTROL ACETATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ACARBOSE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ALBUMIN HUMAN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
AMLODIPINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BERBERINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BIFIDOBACTERIUM SPP.	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CHLORMADINONE ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CHROMIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CLOMIPHENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CLOMIPHENE CITRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEGARELIX	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DIAZOXIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ESTROGEN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FENOFIBRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FOLLITROPIN ALFA	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEUPROLIDE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEVOTHYROXINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MAGNESIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MELATONIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OMEGA-3 FATTY ACIDS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ROSIGLITAZONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SOMATROPIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRIPTORELIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
UROFOLLITROPIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACETYLCYSTEINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BROMOCRIPTINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CALCIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CETRORELIX	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CETRORELIX ACETATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CINNAMON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CORIFOLLITROPIN ALFA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DAPAGLIFLOZIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DESOGESTREL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DROSPIRENONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ETHINYL ESTRADIOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EXENATIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOLLITROPIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOLLITROPIN BETA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GONADORELIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GONADORELIN ACETATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INOSITOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LETROZOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEVONORGESTREL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LIPOIC ACID, ALPHA	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LIRAGLUTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MARVELON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MEDROXYPROGESTERONE ACETATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MENOTROPINS	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PHENTERMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SAXAGLIPTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SEMAGLUTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIMVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TOPIRAMATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ACETYLCARNITINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANAKINRA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARGININE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARTENIMOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CABERGOLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CARNITINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHIGLITAZAR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHORIOGONADOTROPIN ALFA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CYPROTERONE ACETATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIENOGEST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ELAGOLIX	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMPAGLIFLOZIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUTAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GONADOTROPIN, CHORIONIC	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IBUPROFEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEVOCARNITINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LICOGLIFLOZIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METFORMIN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OLIVE OIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ORLISTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OXYTOCIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAVINETANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PENTOXIFYLLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PROGESTERONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QUERCETIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RESVERATROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SALSALATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SITAGLIPTIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SPIRONOLACTONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
THYMOQUINONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TILDACERFONT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UBIDECARENONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VILDAGLIPTIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VITAMIN E	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASTAXANTHIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BICALUTAMIDE	Small molecule	Phase I	Emerging	35	2 trials 1 Trial pubs 1 RCT View evidence Registry trials NCT05979389 — Bicalutamide Therapy in Young Women With NAFLD and PCOS (RECRUITING) PHASE1 NCT05647356 — The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2 (UNKNOWN) NA Published literature Clinical trial publication Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial (The Journal of clinical endocrinology and metabolism, 2018) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
CANAGLIFLOZIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DYDROGESTERONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ESTRADIOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ESTRADIOL VALERATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FISH OIL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FOLIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GANIRELIX	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GESTODENE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ICOSAPENT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ISOSORBIDE MONONITRATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MAZDUTIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NOMEGESTROL ACETATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ACARBOSE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ALBUMIN HUMAN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
AMLODIPINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BERBERINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BIFIDOBACTERIUM SPP.	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CHLORMADINONE ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CHROMIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CLOMIPHENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CLOMIPHENE CITRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEGARELIX	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DIAZOXIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ESTROGEN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FENOFIBRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FOLLITROPIN ALFA	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEUPROLIDE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEVOTHYROXINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MAGNESIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MELATONIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OMEGA-3 FATTY ACIDS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ROSIGLITAZONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SOMATROPIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRIPTORELIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
UROFOLLITROPIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ABIRATERONE ACETATE Repurposing via CHEK2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ACETAZOLAMIDE Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AMPHETAMINE Repurposing via ADCY5	Small molecule	Approved	Strong	95	4 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
BICALUTAMIDE Repurposing via ADCY5	Small molecule	Approved	Strong	95	2 trials 1 Trial pubs 1 RCT View evidence Registry trials NCT05979389 — Bicalutamide Therapy in Young Women With NAFLD and PCOS (RECRUITING) PHASE1 NCT05647356 — The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2 (UNKNOWN) NA Published literature Clinical trial publication Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial (The Journal of clinical endocrinology and metabolism, 2018) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CARBACHOL Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CIPROFLOXACIN Repurposing via ADCY5	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIAZEPAM Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIBOTERMIN ALFA Repurposing via BMPR1B	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ENZALUTAMIDE Repurposing via CHEK2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
EPIRUBICIN Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EPTOTERMIN ALFA Repurposing via BMPR1B	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUMAZENIL Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
GEFITINIB Repurposing via CHEK2	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
IMIPRAMINE Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing via ADCY5	Small molecule	Approved	Strong	95	3 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing via ADCY5	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
MAFENIDE Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METFORMIN HYDROCHLORIDE Repurposing via COXFA4L2	Small molecule	Approved	Strong	95	8 trials 5 Trial pubs 3 RCT View evidence Registry trials NCT02689843 — Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS (COMPLETED) EARLY_PHASE1 NCT01482286 — Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS (TERMINATED) PHASE3 NCT03086005 — Study to Assess the Effect of Metformin Supplementation on IVF Outcome in Patients With Polycystic Ovarian Syndrome. (COMPLETED) PHASE3 NCT02635386 — EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) (COMPLETED) PHASE3 NCT00471523 — Treatment of Anovulatory Infertility in PCOS Patients (COMPLETED) PHASE4 NCT02341703 — Ovulation Induction in Clomiphene Citrate Resistant PCO Women (COMPLETED) EARLY_PHASE1 NCT03259919 — Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study (COMPLETED) PHASE2 NCT07399535 — Clinical Investigation of Herbal Formulation and Its Efficacy in Polycystic Ovarian Syndrome (COMPLETED) PHASE1 Published literature Clinical trial publication Bioequivalence of Related GelShield(Ⓡ) Sustained-release Formulations of Metformin: A Pooled Pharmacokinetic Analysis (Clinical therapeutics, 2024) Clinical trial publication [Efficacy and mechanism of electroacupuncture on insulin resistant polycystic ovary syndrome] (Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2020) Clinical trial publication [Observation on therapeutic effect of polycystic ovary syndrome of damp-phlegm constitution treated with embedding therapy on back-shu points and front-mu points combined with needle-pricking therapy on Sifeng (EX-UE 10)] (Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2014) Clinical trial publication Effect of metformin on the level of anti-Mullerian hormone in therapy of polycystic ovary syndrome in obese women (Minerva ginecologica, 2014) Clinical trial publication Effect of metformin hydrochloride in correcting hyperinsulinemia and high leptin levels in treatment of infertile polycystic patients (Journal of Ayub Medical College, Abbottabad : JAMC, 2013) CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
METHAZOLAMIDE Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NALIDIXIC ACID Repurposing via ADCY5	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NICOTINE Repurposing via ADCY5	Small molecule	Approved	Strong	95	4 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NIRAPARIB Repurposing via CHEK2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NORFLOXACIN Repurposing via ADCY5	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
OFLOXACIN Repurposing via ADCY5	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
OLAPARIB Repurposing via CHEK2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PALBOCICLIB Repurposing via CHEK2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PHENYTOIN Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PRAZOSIN Repurposing via ADCY5	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
PREDNISONE Repurposing via CHEK2	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
RUCAPARIB Repurposing via CHEK2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
SIROLIMUS Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SULBACTAM Repurposing via ADCY5	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TALAZOPARIB Repurposing via CHEK2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
TAZOBACTAM Repurposing via ADCY5	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
TROGLITAZONE Repurposing via ADCY5	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VEMURAFENIB Repurposing via CHEK2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DARAPLADIB Repurposing via ADCY5	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing via ADCY5	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
CHEMBL:CHEMBL401844 Repurposing via ADCY5	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
FD6 Repurposing via ADCY5	Small molecule	Phase II	Emerging	50	—	DGIdb	—
NKY80 Repurposing via ADCY5	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ALPRENOLOL Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing via ADCY5	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets

Natural Products

111 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Folate Natural product Human Study Folate improves the effect of metformin treatment on vascular endotheli… Human Study Folate supplementation for 8 weeks among women with PCOS had beneficial… Human Study Myo-inositol plus folic acid has a beneficial effect in improving ovari…	Nutraceutical	Approved	Emerging	19	8 trials 5 Trial pubs 5 RCT View evidence Registry trials NCT02802215 — Metformin for Prevention Gestational Diabetes in Pregnant Women With Polycystic Ovarian Syndrome (UNKNOWN) PHASE2, PHASE3 NCT04670393 — Antioxidant Supplement Associated With Oral Probiotics in Patients With PCOS in IVF (COMPLETED) NA NCT03585738 — Effects of Oral Inositol Supplementation on Obstetrics Outcomes in PCOS Women (NOT_YET_RECRUITING) NA NCT02344888 — Adding Prednisolone During Ovulation Induction With CC in Lean Women With CC Resistant PCOS (UNKNOWN) PHASE4 NCT03673995 — Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS (COMPLETED) NA NCT07629895 — Myo-Inositol Alone Versus Myo-Inositol Plus Alpha-Lactalbumin in Women With Polycystic Ovary Syndrome (NOT_YET_RECRUITING) NA NCT04204044 — Comparison of Myoinositol and Metformin in PCO (UNKNOWN) EARLY_PHASE1 NCT06158932 — A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance (COMPLETED) NA CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Vitamin D3 Natural product Cochrane review Effect of vitamin D on biochemical parameters in polycystic ovary syndr… Meta Analysis, Review Vitamin E can positively affect metabolic and hormonal parameters in wo… Meta Analysis Serum 25-hydroxyvitamin D, follicle stimulating hormone and sex hormone…	Nutraceutical	Approved	Emerging	19	8 trials 1 Cochrane View evidence Registry trials NCT00743574 — Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome) (COMPLETED) NA NCT04670393 — Antioxidant Supplement Associated With Oral Probiotics in Patients With PCOS in IVF (COMPLETED) NA NCT06045351 — Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome (RECRUITING) PHASE1 NCT06101147 — Effect of Vitamin D Supplementation on Testosterone Level in Women With Polycystic Ovary Syndrome (COMPLETED) PHASE2 NCT02656121 — Correction of Vitamin D Deficiency and Its Effect on Ovulation Induction in Women With PCOS (VIDEO): A Feasibility RCT (COMPLETED) PHASE2 NCT05101811 — Vitamin D Levels in Women With Polycystic Ovary Syndrome (COMPLETED) PHASE4 NCT06158932 — A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance (COMPLETED) NA NCT02865187 — Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction (COMPLETED) NA Published literature Cochrane review Effect of vitamin D on biochemical parameters in polycystic ovary syndrome women: a meta-analysis (Archives of gynecology and obstetrics, 2017) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Omega-3 Fatty Acids Natural product Human Study Flaxseed oil omega-3 supplementation for 12 weeks in women with PCOS ha… Human Study Omega-3 fatty acids supplementation for 12 weeks in PCOS women signific… Human Study The influences of vitamin D and omega-3 co-supplementation on clinical,…	Nutraceutical	Phase II	Emerging	19	8 trials 4 Cochrane View evidence Registry trials NCT06545721 — Weight Cycling on Hyperandrogenemia and Insulin Resistance in Polycystic Ovary Syndrome (RECRUITING) NA NCT05597111 — Comparison of Docosahexaenoic (DHA) Values in Patients With Polycystic Ovary Syndrome (PCOS) (UNKNOWN) NCT07036952 — Effect of Omega-3 Supplementation as Add on Therapy on Metabolic Syndrome in Women With Polycystic Ovary Syndrome. (ENROLLING_BY_INVITATION) NA NCT01766557 — Assessment of Cod Protein as an Insulin-sensitizing Agent in Women With Polycystic Ovary Syndrome. (COMPLETED) NA NCT04116203 — Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS) (COMPLETED) PHASE1 NCT07604870 — Krill Oil and Metformin in Women With PCOS and Metabolically Unhealthy Obesity (COMPLETED) PHASE2 NCT03306745 — Micronutrient Supplementation in PCO-syndrome (COMPLETED) NA NCT01189669 — n-3 Polyunsaturated Fatty Acids (PUFA) Supplementation in Young Women With Polycystic Ovary Syndrome (PCOS) (COMPLETED) NA CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Calcium Natural product Clinical trial publication Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospec… Clinical trial publication The effect of calorie-restriction along with thylakoid membranes of spi… Clinical trial publication Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in W…	Nutraceutical	Approved	Emerging	19	7 trials 15 Trial pubs View evidence Registry trials NCT00743574 — Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome) (COMPLETED) NA NCT06045351 — Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome (RECRUITING) PHASE1 NCT04117750 — Impact of Vitamin D Supplementation on Cardiometabolic Status and Androgen Profile in Polycystic Ovary Syndrome (COMPLETED) NA NCT03396380 — Effect of Vitamin D Supplement in Induction of Ovulation in Overweight Women With Polycystic Ovary Syndrome (UNKNOWN) PHASE3 NCT01672801 — Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT (COMPLETED) NA NCT03792984 — The Effect of Calcium and Vitamin D Supplements on Metabolic and Hormonal Disturbances in Polycystic Ovary Syndrome Patients (COMPLETED) PHASE3 NCT01360996 — Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism (COMPLETED) PHASE4 Published literature Clinical trial publication Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospective Double-Blind Two-Phase Randomized Controlled Clinical Trial (Nutrients, 2025) Clinical trial publication The effect of calorie-restriction along with thylakoid membranes of spinach on the gut-brain Axis Pathway and oxidative stress biomarkers in obese women with polycystic ovary syndrome: a Randomized, Double-blind, placebo-controlled clinical trial (Journal of ovarian research, 2023) Clinical trial publication Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial (Advances in therapy, 2021) Clinical trial publication The efficacy of vitamin D combined with clomiphene citrate in ovulation induction in overweight women with polycystic ovary syndrome: a double blind, randomized clinical trial (Endocrine, 2020) Clinical trial publication A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome (Archives of Iranian medicine, 2017) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Berberine Natural product Meta Analysis, Review Berberine showed a promising prospect in treating polycystic ovary synd… Human Study Berberine can represent a safe novel dietary supplement, helpful in tre… Human Study The role of serum inflammatory cytokines and berberine in the insulin s…	Botanical	Phase II	Emerging	16	5 trials View evidence Registry trials NCT07465575 — Berberine Phytosome for Signs and Symptoms of Polycystic Ovary Syndrome (PCOS) (NOT_YET_RECRUITING) NA NCT01116167 — Polycystic Ovary Syndrome (PCOS): Effect Of Letrozole and Berberine (UNKNOWN) NA NCT04932070 — Berberine and Polycystic Ovary Syndrome (COMPLETED) NA NCT05480670 — Treatment Benefits of Berberine Supplementation for Women With PCOS (COMPLETED) NA NCT01138930 — Effect of Berberine on Hormonal and Metabolic Features in Obese Women With Polycystic Ovary Syndrome (PCOS) (UNKNOWN) NA CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Alpha-Lipoic Acid Natural product Clinical trial publication HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS)… Clinical trial publication [Evaluation of a new association between insulin-sensitizers and α-lipo… Human Study Alpha lipoic acid administration improved both peripheral sensitivity t…	Nutraceutical	Approved	Emerging	16	8 trials 2 Trial pubs View evidence Registry trials NCT05231980 — Efficacy of Pentoxifylline and Alpha Lipoic Acid in PCOS Resistant to Clomiphene Citrate (COMPLETED) PHASE2 NCT04881851 — Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment (TERMINATED) NA NCT07630779 — Efficacy of Alpha Lipoic Acid Combined With Myo-Inositol in Non-Diabetic PCOS Patients (RECRUITING) PHASE3 NCT02666170 — Effects of Alpha-acid Lipoic in PCOS Women (UNKNOWN) NA NCT06418347 — Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females (UNKNOWN) PHASE3 NCT07182526 — Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome (RECRUITING) PHASE2 NCT03177122 — Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology (UNKNOWN) PHASE4 NCT00505427 — Alpha Lipoic Acid and Polycystic Ovary Syndrome (COMPLETED) PHASE1 Published literature Clinical trial publication HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA) (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2020) Clinical trial publication [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS] (Minerva ginecologica, 2013) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Chromium Natural product Effectiveness of mineral supplements (magnesium, chromium, zinc, seleni… The effectiveness of nutritional supplements in improving polycystic ov… Comparison of nutritional supplements in improving glycolipid metabolis…	Nutraceutical	Phase III	Emerging	16	5 trials 6 Cochrane 8 Meta-analysis View evidence Registry trials NCT03503201 — Effect of Chromium Supplementation on Intracytoplasmatic Sperm Injection (ICSI) Outcomes in Polycystic Ovary Syndrome Ladies (COMPLETED) NA NCT03673995 — Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS (COMPLETED) NA NCT02328404 — The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome (PCOS) (COMPLETED) PHASE3 NCT06405243 — Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients (UNKNOWN) PHASE3 NCT05765305 — Combined Chromium With Letrozole Versus Letrozole Only in Induction of Ovulation in Patients With Polycystic Ovary Syndrome (COMPLETED) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Vitamin D3 Natural product Cochrane review Effect of vitamin D on biochemical parameters in polycystic ovary syndr… Meta Analysis Serum 25-hydroxyvitamin D, follicle stimulating hormone and sex hormone… Meta Analysis Serum level of vitamin D was associated with the risk of polycystic ova…	Nutraceutical	Approved	Emerging	10	8 trials 1 Cochrane View evidence Registry trials NCT00743574 — Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome) (COMPLETED) NA NCT04670393 — Antioxidant Supplement Associated With Oral Probiotics in Patients With PCOS in IVF (COMPLETED) NA NCT06045351 — Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome (RECRUITING) PHASE1 NCT06101147 — Effect of Vitamin D Supplementation on Testosterone Level in Women With Polycystic Ovary Syndrome (COMPLETED) PHASE2 NCT02656121 — Correction of Vitamin D Deficiency and Its Effect on Ovulation Induction in Women With PCOS (VIDEO): A Feasibility RCT (COMPLETED) PHASE2 NCT05101811 — Vitamin D Levels in Women With Polycystic Ovary Syndrome (COMPLETED) PHASE4 NCT06158932 — A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance (COMPLETED) NA NCT02865187 — Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction (COMPLETED) NA Published literature Cochrane review Effect of vitamin D on biochemical parameters in polycystic ovary syndrome women: a meta-analysis (Archives of gynecology and obstetrics, 2017) CT.gov search · Cochrane · PubMed		PubChem
N-Acetylcysteine Natural product Cochrane review Letrozole for Ovulation Induction in Women With Polycystic Ovary Syndro… Cochrane review Efficacy of N-Acetylcysteine in Polycystic Ovary Syndrome: Systematic R… Cochrane review Type and Frequency in Use of Nutraceutical and Micronutrient Supplement…	Amino acid	Approved	Emerging	10	5 trials 5 Cochrane 2 Meta-analysis 6 Trial pubs 6 RCT View evidence Registry trials NCT06836128 — The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients (RECRUITING) PHASE3 NCT02775734 — NAC in CC Resistant PCOS After LOD (COMPLETED) PHASE2, PHASE3 NCT02239107 — N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome (COMPLETED) PHASE4 NCT01896492 — Clomiphene Plus N-acetyl Cysteine for Induction of Ovulation in Newly Diagnosed Pcos. (COMPLETED) PHASE4 NCT01008046 — N-acetyl Cysteine and Clomiphene Citrate or Metformin and Clomiphene Citrate for Women With CC Resistant Polycystic Ovary Syndrome (PCOS). (COMPLETED) NA Published literature Cochrane review Letrozole for Ovulation Induction in Women With Polycystic Ovary Syndrome (Obstetrical & gynecological survey, 2026) Cochrane review Efficacy of N-Acetylcysteine in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis (Nutrients, 2025) Cochrane review Type and Frequency in Use of Nutraceutical and Micronutrient Supplementation for the Management of Polycystic Ovary Syndrome: A Systematic Scoping Review (Biomedicines, 2023) Cochrane review The effects of N-acetylcysteine supplement on metabolic parameters in women with polycystic ovary syndrome: a systematic review and meta-analysis (Frontiers in nutrition, 2023) Cochrane review The effects of N-acetylcysteine on ovulation and sex hormones profile in women with polycystic ovary syndrome: a systematic review and meta-analysis (The British journal of nutrition, 2023) Systematic review A review of antioxidant N-acetylcysteine in addressing polycystic ovary syndrome (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2024) Clinical trial publication N-acetylcysteine supplementation improves endocrine-metabolism profiles and ovulation induction efficacy in polycystic ovary syndrome (Journal of ovarian research, 2024) Clinical trial publication Evaluation of the efficacy of an antioxidant combination for the modulation of metabolic, endocrine, and clinical parameters in patients with polycystic ovary syndrome (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2023) Clinical trial publication Randomized controlled trial of N-acetylcysteine versus l-carnitine among women with clomiphene-citrate-resistant polycystic ovary syndrome (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2019) Clinical trial publication The adjuvant effect of metformin and N-acetylcysteine to clomiphene citrate in induction of ovulation in patients with Polycystic Ovary Syndrome (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2015) Clinical trial publication N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin (Reproduction, fertility, and development, 2016) CT.gov search · Cochrane · PubMed		PubChem
Vitamin E Natural product Meta-analysis Vitamin E supplementation improves testosterone, glucose- and lipid-rel… Meta-analysis The effectiveness of coenzyme Q10, vitamin E, inositols, and vitamin D… Systematic review Efficacy of dietary supplements as an adjunctive therapy for polycystic…	Nutraceutical	Phase II	Emerging	10	2 trials 3 Cochrane 5 Meta-analysis 11 Trial pubs 10 RCT View evidence Registry trials NCT03306745 — Micronutrient Supplementation in PCO-syndrome (COMPLETED) NA NCT03674385 — Efficacy of Vit E in PCOS Resistant to Clomiphene Citrate (COMPLETED) PHASE2 Published literature Meta-analysis Vitamin E supplementation improves testosterone, glucose- and lipid-related metabolism in women with polycystic ovary syndrome: a meta-analysis of randomized clinical trials (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2022) Meta-analysis The effectiveness of coenzyme Q10, vitamin E, inositols, and vitamin D in improving the endocrine and metabolic profiles in women with polycystic ovary syndrome: a network Meta-analysis (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2021) Systematic review Efficacy of dietary supplements as an adjunctive therapy for polycystic ovary syndrome: an umbrella meta-analysis (Frontiers in nutrition, 2025) Systematic review Nutraceuticals and polycystic ovary syndrome: a systematic review of the literature (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2022) Clinical trial publication Randomized controlled open-label study of the effect of vitamin E supplementation on fertility in clomiphene citrate-resistant polycystic ovary syndrome (The journal of obstetrics and gynaecology research, 2020) Clinical trial publication Effect of a short-term vitamin E supplementation on oxidative stress in infertile PCOS women under ovulation induction: a retrospective cohort study (BMC women's health, 2020) Clinical trial publication Independent and Additive Effects of Coenzyme Q10 and Vitamin E on Cardiometabolic Outcomes and Visceral Adiposity in Women With Polycystic Ovary Syndrome (Archives of medical research, 2019) Clinical trial publication The impact of a standardized micronutrient supplementation on PCOS-typical parameters: a randomized controlled trial (Archives of gynecology and obstetrics, 2019) Clinical trial publication Omega-3 and vitamin E co-supplementation can improve antioxidant markers in obese/overweight women with polycystic ovary syndrome (International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 2020) Randomized controlled trial The Effects of Magnesium and Vitamin E Co-Supplementation on Hormonal Status and Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome (Biological trace element research, 2019) CT.gov search · Cochrane · PubMed		PubChem
Folate Natural product Human Study Administration of B-group vitamins reduces circulating homocysteine in… Human Study Folate improves the effect of metformin treatment on vascular endotheli… Human Study Folate supplementation for 8 weeks among women with PCOS had beneficial…	Nutraceutical	Approved	Emerging	10	8 trials 5 Trial pubs 5 RCT View evidence Registry trials NCT02802215 — Metformin for Prevention Gestational Diabetes in Pregnant Women With Polycystic Ovarian Syndrome (UNKNOWN) PHASE2, PHASE3 NCT04670393 — Antioxidant Supplement Associated With Oral Probiotics in Patients With PCOS in IVF (COMPLETED) NA NCT03585738 — Effects of Oral Inositol Supplementation on Obstetrics Outcomes in PCOS Women (NOT_YET_RECRUITING) NA NCT02344888 — Adding Prednisolone During Ovulation Induction With CC in Lean Women With CC Resistant PCOS (UNKNOWN) PHASE4 NCT03673995 — Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS (COMPLETED) NA NCT07629895 — Myo-Inositol Alone Versus Myo-Inositol Plus Alpha-Lactalbumin in Women With Polycystic Ovary Syndrome (NOT_YET_RECRUITING) NA NCT04204044 — Comparison of Myoinositol and Metformin in PCO (UNKNOWN) EARLY_PHASE1 NCT06158932 — A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance (COMPLETED) NA CT.gov search · Cochrane · PubMed		PubChem
Magnesium Natural product Cochrane review Effectiveness of mineral supplements (magnesium, chromium, zinc, seleni… Cochrane review New Perspectives on Nutraceutical Insulin Sensitizing Agents in the Tre… Cochrane review Does Magnesium Affect Sex Hormones and Cardiometabolic Risk Factors in…	Nutraceutical	Approved	Emerging	10	7 trials 5 Cochrane 7 Meta-analysis 10 Trial pubs 9 RCT View evidence Registry trials NCT03617263 — Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII) (TERMINATED) PHASE2 NCT04306692 — Myo-inositol Versus Clomiphene Citrate in PCOS (TERMINATED) PHASE4 NCT07298564 — Effect of Magnesium and Levocarnitine on Metabolic and Clinical Outcomes in Women With Polycystic Ovarian Syndrome (PCOS) (RECRUITING) NA NCT04593459 — Probiotic Intervention in PCOS (COMPLETED) PHASE4 NCT07322120 — Light Fasting Diet and Magnesium in Polycystic Ovary Syndrome (PCOS) (NOT_YET_RECRUITING) NA NCT02178150 — Effect of Magnesium Supplementation on Polycystic Ovary Syndrome (UNKNOWN) NA NCT02521753 — Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients (TERMINATED) NA Published literature Cochrane review Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials (BMC endocrine disorders, 2026) Cochrane review New Perspectives on Nutraceutical Insulin Sensitizing Agents in the Treatment of Psoriasis and Other Dermatological Diseases (International journal of molecular sciences, 2025) Cochrane review Does Magnesium Affect Sex Hormones and Cardiometabolic Risk Factors in Patients with PCOS? Findings from a Systematic Review and Meta-Analysis (Medicina (Kaunas, Lithuania), 2025) Cochrane review A meta-analysis of effects of vitamin E supplementation alone and in combination with omega-3 or magnesium on polycystic ovary syndrome (Scientific reports, 2022) Cochrane review Associations Between Serum Magnesium Concentrations and Polycystic Ovary Syndrome Status: a Systematic Review and Meta-analysis (Biological trace element research, 2021) Meta-analysis Comparison of dietary and physical activity behaviors in women with and without polycystic ovary syndrome: a systematic review and meta-analysis of 39 471 women (Human reproduction update, 2022) Meta-analysis Vitamin E supplementation improves testosterone, glucose- and lipid-related metabolism in women with polycystic ovary syndrome: a meta-analysis of randomized clinical trials (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2022) Clinical trial publication The Effect of Magnesium Supplementation on Insulin Resistance and Metabolic Profiles in Women with Polycystic Ovary Syndrome: a Randomized Clinical Trial (Biological trace element research, 2024) Clinical trial publication The effects of magnesium supplementation on abnormal uterine bleeding, alopecia, quality of life, and acne in women with polycystic ovary syndrome: a randomized clinical trial (Reproductive biology and endocrinology : RB&E, 2022) Clinical trial publication Effects of Melatonin and/or Magnesium Supplementation on Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial (Biological trace element research, 2022) Clinical trial publication Clinical and Metabolic Responses to Magnesium Supplementation in Women with Polycystic Ovary Syndrome (Biological trace element research, 2020) Clinical trial publication Status of Serum Copper, Magnesium, and Total Antioxidant Capacity in Patients with Polycystic Ovary Syndrome (Biological trace element research, 2020) CT.gov search · Cochrane · PubMed		PubChem
Omega-3 Fatty Acids Natural product Human Study Flaxseed oil omega-3 supplementation for 12 weeks in women with PCOS ha… Human Study Omega-3 fatty acids supplementation for 12 weeks in PCOS women signific… Human Study The influences of vitamin D and omega-3 co-supplementation on clinical,…	Nutraceutical	Phase II	Emerging	10	8 trials 4 Cochrane View evidence Registry trials NCT06545721 — Weight Cycling on Hyperandrogenemia and Insulin Resistance in Polycystic Ovary Syndrome (RECRUITING) NA NCT05597111 — Comparison of Docosahexaenoic (DHA) Values in Patients With Polycystic Ovary Syndrome (PCOS) (UNKNOWN) NCT07036952 — Effect of Omega-3 Supplementation as Add on Therapy on Metabolic Syndrome in Women With Polycystic Ovary Syndrome. (ENROLLING_BY_INVITATION) NA NCT01766557 — Assessment of Cod Protein as an Insulin-sensitizing Agent in Women With Polycystic Ovary Syndrome. (COMPLETED) NA NCT04116203 — Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS) (COMPLETED) PHASE1 NCT07604870 — Krill Oil and Metformin in Women With PCOS and Metabolically Unhealthy Obesity (COMPLETED) PHASE2 NCT03306745 — Micronutrient Supplementation in PCO-syndrome (COMPLETED) NA NCT01189669 — n-3 Polyunsaturated Fatty Acids (PUFA) Supplementation in Young Women With Polycystic Ovary Syndrome (PCOS) (COMPLETED) NA CT.gov search · Cochrane · PubMed		PubChem
Zinc Natural product Cochrane review Effectiveness of mineral supplements (magnesium, chromium, zinc, seleni… Cochrane review Zinc supplementation for the prevention of type 2 diabetes mellitus in… Cochrane review Zinc supplementation for the prevention of type 2 diabetes mellitus	Nutraceutical	Preclinical	Emerging	10	1 trials 3 Cochrane 6 Meta-analysis 7 Trial pubs 7 RCT View evidence Registry trials NCT06551285 — Study of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome. (RECRUITING) NA Published literature Cochrane review Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials (BMC endocrine disorders, 2026) Cochrane review Zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance (The Cochrane database of systematic reviews, 2015) Cochrane review Zinc supplementation for the prevention of type 2 diabetes mellitus (The Cochrane database of systematic reviews, 2007) Meta-analysis Comparison of dietary and physical activity behaviors in women with and without polycystic ovary syndrome: a systematic review and meta-analysis of 39 471 women (Human reproduction update, 2022) Meta-analysis Leveraging Northern European population history: novel low-frequency variants for polycystic ovary syndrome (Human reproduction (Oxford, England), 2022) Meta-analysis Serum Trace Elements in Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis (Frontiers in endocrinology, 2020) Meta-analysis Zinc status and polycystic ovarian syndrome: A systematic review and meta-analysis (Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2019) Clinical trial publication Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment (Endocrine journal, 2019) Clinical trial publication A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome (Archives of Iranian medicine, 2017) Clinical trial publication The Effects of Magnesium and Zinc Co-Supplementation on Biomarkers of Inflammation and Oxidative Stress, and Gene Expression Related to Inflammation in Polycystic Ovary Syndrome: a Randomized Controlled Clinical Trial (Biological trace element research, 2018) Clinical trial publication Magnesium-Zinc-Calcium-Vitamin D Co-supplementation Improves Hormonal Profiles, Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial (Biological trace element research, 2018) Clinical trial publication Effects of Zinc Supplementation on Endocrine Outcomes in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial (Biological trace element research, 2016) CT.gov search · Cochrane · PubMed		PubChem
Garlic Natural product Clinical trial publication Efficacy of garlic (Allium sativum) on metabolic syndrome components in… Clinical trial publication The effect of garlic (Allium sativum) supplementation on the lipid para… Human Study The present study indicates that garlic supplementation could be benefi…	Food compound	Preclinical	Emerging	10	2 trials 2 Trial pubs 2 RCT View evidence Registry trials NCT07385716 — Evaluation of the Effect of Time-Restricted Feeding and Mediterranean Diet Model in Women With Polycystic Ovary Syndrome (COMPLETED) NA NCT06610812 — "KETOGENIC MEDITERRANEAN VERSUS HYPOCALORIC BALANCED DIET ON POLYCYSTIC OVARIAN ADOLESCENTS" (COMPLETED) NA Published literature Clinical trial publication Efficacy of garlic (Allium sativum) on metabolic syndrome components in women with polycystic ovary syndrome: randomized controlled trial (Journal of health, population, and nutrition, 2025) Clinical trial publication The effect of garlic (Allium sativum) supplementation on the lipid parameters and blood pressure levels in women with polycystic ovary syndrome: A randomized controlled trial (Phytotherapy research : PTR, 2021) CT.gov search · Cochrane · PubMed		PubChem
Vitamin C Natural product Cochrane review New Perspectives on Nutraceutical Insulin Sensitizing Agents in the Tre… Systematic review Diet's total antioxidant capacity and women's health: systematic review… Meta Analysis, Review Vitamin E can positively affect metabolic and hormonal parameters in wo…	Nutraceutical	Approved	Emerging	10	4 trials 1 Cochrane 1 Trial pubs View evidence Registry trials NCT04010942 — Vitamin D for Polycystic Ovary Syndrome Clomiphene Resistant Women (COMPLETED) PHASE4 NCT03049462 — The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists (RECRUITING) PHASE1 NCT05885633 — Endometrial Vitamin D Receptor in PCOS (COMPLETED) NA NCT00593294 — Oral Contraceptive and Cardiovascular Risk in PCOS (COMPLETED) PHASE4 Published literature Cochrane review New Perspectives on Nutraceutical Insulin Sensitizing Agents in the Treatment of Psoriasis and Other Dermatological Diseases (International journal of molecular sciences, 2025) Systematic review Diet's total antioxidant capacity and women's health: systematic review and meta-analysis (The British journal of nutrition, 2025) CT.gov search · Cochrane · PubMed		PubChem
Vitamin B12 Natural product Cochrane review The effect of metformin on homocysteine levels in patients with polycys… Cochrane review Vitamin B12 status in metformin treated patients: systematic review Meta-analysis Homocysteine, vitamin B12, and folate circulating levels in women with…	Nutraceutical	Approved	Emerging	10	3 trials 2 Cochrane 3 Meta-analysis 2 Trial pubs 2 RCT View evidence Registry trials NCT01514942 — Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters (COMPLETED) PHASE4 NCT00670800 — Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome (COMPLETED) NA NCT06124300 — Effects of a Female Hormone Balance Supplement on Symptoms of Polycystic Ovary Syndrome and Severe Premenstrual Syndrome (COMPLETED) NA Published literature Cochrane review The effect of metformin on homocysteine levels in patients with polycystic ovary syndrome: A systematic review and meta-analysis (The journal of obstetrics and gynaecology research, 2021) Cochrane review Vitamin B12 status in metformin treated patients: systematic review (PloS one, 2014) Meta-analysis Homocysteine, vitamin B12, and folate circulating levels in women with and without polycystic ovary syndrome: A systematic review and meta-analysis (Women's health (London, England), 2024) Clinical trial publication The comparison of fennel infusion plus dry cupping versus metformin in management of oligomenorrhoea in patients with polycystic ovary syndrome: a randomised clinical trial (Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2019) Clinical trial publication Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome (Acta obstetricia et gynecologica Scandinavica, 2007) CT.gov search · Cochrane · PubMed		PubChem
Vitamin K Natural product Randomized controlled trial Effect of vitamin K2 administration on depression status in patients wi… Randomized controlled trial The Effects of Calcium, Vitamins D and K co-Supplementation on Markers… Randomized controlled trial The Effects of Vitamin D-K-Calcium Co-Supplementation on Endocrine, Inf…	Nutraceutical	Preclinical	Emerging	10	1 Cochrane 3 RCT View evidence Published literature Randomized controlled trial Effect of vitamin K2 administration on depression status in patients with polycystic ovary syndrome: a randomized clinical trial (BMC women's health, 2022) Randomized controlled trial The Effects of Calcium, Vitamins D and K co-Supplementation on Markers of Insulin Metabolism and Lipid Profiles in Vitamin D-Deficient Women with Polycystic Ovary Syndrome (Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2017) Randomized controlled trial The Effects of Vitamin D-K-Calcium Co-Supplementation on Endocrine, Inflammation, and Oxidative Stress Biomarkers in Vitamin D-Deficient Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2016) CT.gov search · Cochrane · PubMed		PubChem
Calcium Natural product Clinical trial publication Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospec… Clinical trial publication The effect of calorie-restriction along with thylakoid membranes of spi… Clinical trial publication Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in W…	Nutraceutical	Approved	Emerging	10	7 trials 15 Trial pubs View evidence Registry trials NCT00743574 — Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome) (COMPLETED) NA NCT06045351 — Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome (RECRUITING) PHASE1 NCT04117750 — Impact of Vitamin D Supplementation on Cardiometabolic Status and Androgen Profile in Polycystic Ovary Syndrome (COMPLETED) NA NCT03396380 — Effect of Vitamin D Supplement in Induction of Ovulation in Overweight Women With Polycystic Ovary Syndrome (UNKNOWN) PHASE3 NCT01672801 — Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT (COMPLETED) NA NCT03792984 — The Effect of Calcium and Vitamin D Supplements on Metabolic and Hormonal Disturbances in Polycystic Ovary Syndrome Patients (COMPLETED) PHASE3 NCT01360996 — Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism (COMPLETED) PHASE4 Published literature Clinical trial publication Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospective Double-Blind Two-Phase Randomized Controlled Clinical Trial (Nutrients, 2025) Clinical trial publication The effect of calorie-restriction along with thylakoid membranes of spinach on the gut-brain Axis Pathway and oxidative stress biomarkers in obese women with polycystic ovary syndrome: a Randomized, Double-blind, placebo-controlled clinical trial (Journal of ovarian research, 2023) Clinical trial publication Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial (Advances in therapy, 2021) Clinical trial publication The efficacy of vitamin D combined with clomiphene citrate in ovulation induction in overweight women with polycystic ovary syndrome: a double blind, randomized clinical trial (Endocrine, 2020) Clinical trial publication A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome (Archives of Iranian medicine, 2017) CT.gov search · Cochrane · PubMed		PubChem
Berberine Natural product Meta Analysis, Review Berberine showed a promising prospect in treating polycystic ovary synd… Human Study Berberine can represent a safe novel dietary supplement, helpful in tre… Human Study The role of serum inflammatory cytokines and berberine in the insulin s…	Botanical	Preclinical	Emerging	7	5 trials View evidence Registry trials NCT07465575 — Berberine Phytosome for Signs and Symptoms of Polycystic Ovary Syndrome (PCOS) (NOT_YET_RECRUITING) NA NCT01116167 — Polycystic Ovary Syndrome (PCOS): Effect Of Letrozole and Berberine (UNKNOWN) NA NCT04932070 — Berberine and Polycystic Ovary Syndrome (COMPLETED) NA NCT05480670 — Treatment Benefits of Berberine Supplementation for Women With PCOS (COMPLETED) NA NCT01138930 — Effect of Berberine on Hormonal and Metabolic Features in Obese Women With Polycystic Ovary Syndrome (PCOS) (UNKNOWN) NA CT.gov search · Cochrane · PubMed		PubChem
Curcumin Natural product Meta Analysis, Review Curcumin may have the potential to enhance cardiometabolic health by re… Human Study Curcumin might be a safe and useful supplement to ameliorate PCOS-assoc… Human Study Curcumin seems to be an efficient reducer of oxidative stress related c…	Food compound	Preclinical	Emerging	7	—		PubChem
Cinnamon Natural product Meta Analysis Cinnamon can be used as an anti-diabetic agent and an add-on treatment… Human Study Cinnamon reduces insulin resistance parameters in polycystic ovary synd… Human Study Cinnamon supplementation improved antioxidant status and serum lipid pr…	Botanical	Preclinical	Emerging	7	—		PubChem
Alpha-Lipoic Acid Natural product Clinical trial publication HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS)… Clinical trial publication [Evaluation of a new association between insulin-sensitizers and α-lipo… Human Study Alpha lipoic acid administration improved both peripheral sensitivity t…	Nutraceutical	Approved	Emerging	7	8 trials 2 Trial pubs View evidence Registry trials NCT05231980 — Efficacy of Pentoxifylline and Alpha Lipoic Acid in PCOS Resistant to Clomiphene Citrate (COMPLETED) PHASE2 NCT04881851 — Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment (TERMINATED) NA NCT07630779 — Efficacy of Alpha Lipoic Acid Combined With Myo-Inositol in Non-Diabetic PCOS Patients (RECRUITING) PHASE3 NCT02666170 — Effects of Alpha-acid Lipoic in PCOS Women (UNKNOWN) NA NCT06418347 — Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females (UNKNOWN) PHASE3 NCT07182526 — Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome (RECRUITING) PHASE2 NCT03177122 — Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology (UNKNOWN) PHASE4 NCT00505427 — Alpha Lipoic Acid and Polycystic Ovary Syndrome (COMPLETED) PHASE1 Published literature Clinical trial publication HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA) (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2020) Clinical trial publication [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS] (Minerva ginecologica, 2013) CT.gov search · Cochrane · PubMed		PubChem
Coenzyme Q10 Natural product Human Study Coenzyme Q10 and vitamin E had beneficial effects on cardiometabolic ou… Human Study CoQ10 and vitamin E supplementation had beneficial effects on serum FBS… Human Study CoQ10 intake for 12 weeks in PCOS women significantly improved gene exp…	Nutraceutical	Preclinical	Emerging	7	—		PubChem
Resveratrol Natural product Human Study A single bout of electroacupuncture remodels epigenetic and transcripti… Human Study Effect of resveratrol on menstrual cyclicity, hyperandrogenism and meta… Human Study Resveratrol may improve some outcomes of PCOS patients.	Food compound	Preclinical	Emerging	7	—		PubChem
Probiotics Natural product Human Study Co-administration of vitamin D and probiotic for 12 weeks to women with… Human Study in the form of a new beverage can improve insulin resistance, insulin,… Human Study Probiotic effects on sexual function in women with polycystic ovary syn…	Probiotic	Preclinical	Emerging	7	—		—
Chamomile Natural product Human Study Oral administration of chamomile capsule caused a significant decrease…	Botanical	Preclinical	Emerging	7	—		—
Quercetin Natural product Meta Analysis, Review This meta-analysis suggested that quercetin has positive effects on PCO… Meta Analysis, Review This meta-analysis suggests that consumption of tea supplementation in… Human Study Quercetin and polycystic ovary syndrome; inflammation, hormonal paramet…	Food compound	Preclinical	Emerging	7	—		PubChem
Melatonin Natural product Meta Analysis, Review This meta-analysis suggests that consumption of tea supplementation in… Meta Analysis, Review Vitamin D supplementation had beneficial on biomarkers of inflammation… Meta Analysis Vitamin D supplementation improves markers of polycystic ovarian syndro…	Nutraceutical	Preclinical	Emerging	7	—		PubChem
Fenugreek Natural product Human Study Beneficial effects of a novel fenugreek seed extract in women with poly… Human Study Furocyst was efficacious in ameliorating the symptoms of polycystic ova…	Botanical	Preclinical	Emerging	7	—		—
Moringa Natural product Assessment of hepatoprotective, nephroprotective efficacy, and antioxid… Moringa oleifera leaf supplementation relieves oxidative stress and reg… Effectiveness of Moringa oleifera Leaves on TNF-α Expression, Insulin L…	Botanical	Preclinical	Emerging	7	—		—
Spirulina Natural product Spirulina versus metformin for controlling some insulin signaling pathw…	Nutraceutical	Preclinical	Emerging	7	—		—
Black Seed Oil Natural product A Narrative Review on Various Oil Extraction Methods, Encapsulation Pro…	Botanical	Preclinical	Emerging	7	—		PubChem
Egcg Natural product Meta Analysis, Review Green tea promotes weight loss in women with polycystic ovary syndrome.	Food compound	Preclinical	Emerging	7	—		PubChem
L-Carnitine Natural product Human Study 12-week L-carnitine supplementation in overweight or obese women with P… Human Study Acetyl-L-carnitine ameliorates metabolic and endocrine alterations in w… Meta Analysis, Review The effects of N-acetylcysteine supplement on metabolic parameters in w…	Amino acid	Preclinical	Emerging	7	—		PubChem
Saffron Natural product Human Study Effects of crocin supplementation on inflammatory markers, lipid profil…	Botanical	Preclinical	Emerging	7	—		PubChem
L-Arginine Natural product Human Study L-arginine appears to counteract the hypertensive properties of estradi…	Amino acid	Preclinical	Emerging	7	—		PubChem
Selenium Natural product Human Study Selenium supplementation for 8 weeks among PCOS women had beneficial ef…	Nutraceutical	Preclinical	Emerging	7	—		PubChem
Licorice Natural product Human Study Licorice reduces serum testosterone in healthy women. Human Study Licorice reduces the side effects of spironolactone in the treatment of…	Botanical	Preclinical	Emerging	2	—		—
(5R)-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Calcimycin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Lestaurtinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Ruxolitinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Fedratinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Alvocidib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Axitinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Pazopanib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Staurosporine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Dorsomorphin Natural product Fisetin ameliorates polycystic ovary syndrome in rats via a mechanistic… Baicalin ameliorates polycystic ovary syndrome through AMP-activated pr… Androgen Stimulates Growth of Mouse Preantral Follicles In Vitro: Inter…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Momelotinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Gilteritinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Asp-3026 Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Saracatinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
At-9283 Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Quizartinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Hymenialdisine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Debromohymenialdisine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
(Z)-octadec-11-enoic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product Meta Analysis Serum 25-hydroxyvitamin D, follicle stimulating hormone and sex hormone… Human Study CoQ10 supplementation had beneficial effects in subjects with PCOS, inv… Human Study Progesterone resistance may play a role in polycystic ovary syndrome	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
(9Z,12Z)-octadeca-9,12-dienoic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product Meta Analysis Serum 25-hydroxyvitamin D, follicle stimulating hormone and sex hormone… Human Study CoQ10 supplementation had beneficial effects in subjects with PCOS, inv… Human Study Progesterone resistance may play a role in polycystic ovary syndrome	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
undecanoic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product Meta Analysis Serum 25-hydroxyvitamin D, follicle stimulating hormone and sex hormone… Human Study CoQ10 supplementation had beneficial effects in subjects with PCOS, inv… Human Study Progesterone resistance may play a role in polycystic ovary syndrome	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
caprylic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product Meta Analysis Serum 25-hydroxyvitamin D, follicle stimulating hormone and sex hormone… Human Study CoQ10 supplementation had beneficial effects in subjects with PCOS, inv… Human Study Progesterone resistance may play a role in polycystic ovary syndrome	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
3-methylbutyric acid [(2S,3R,4R)-2-(4-hydroxy-3-methoxy-phenyl)-4-vanillyl-tetrahydrofuran-3-yl]methyl ester Natural product Meta Analysis Serum 25-hydroxyvitamin D, follicle stimulating hormone and sex hormone… Human Study CoQ10 supplementation had beneficial effects in subjects with PCOS, inv… Human Study Progesterone resistance may play a role in polycystic ovary syndrome	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Formestane Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Testosterone Natural product Human Study An 8-week low-starch/low-dairy diet resulted in weight loss, improved i… Human Study Concentrated pomegranate juice could effectively improve testosterone l… Human Study CoQ10 and vitamin E supplementation had beneficial effects on serum FBS…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Aminoglutethimide Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Clozapine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Cyclohexane-1,2,3,4,5,6-Hexol Natural product	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem
Water Natural product Human Study Exposure to high levels of PFAS in drinking water was associated with i…	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem
Astaxanthin Natural product Human Study Astaxanthin supplementation impact on insulin resistance, lipid profile… Human Study Astaxanthin treatment ameliorates ER stress in polycystic ovary syndrom… Human Study Astaxanthin treatment decreases pro-inflammatory cytokines and improves…	Food compound	Preclinical	Emerging	0	—		PubChem
Pomegranate Natural product Human Study Concentrated pomegranate juice could effectively improve testosterone l… Human Study Consuming daily synbiotic pomegranate juice improved metabolic, oxidati… Human Study in the form of a new beverage can improve insulin resistance, insulin,…	Nutraceutical	Preclinical	Emerging	0	—		—
Cyclohexane-1,2,3,4,5,6-Hexol Natural product Human Study D-chiro-inositol has a therapeutic effect in lean women with the polycy… Human Study Inositol improves ovarian function in women with oligomenorrhea and pol… Human Study Myo-inositol decreases circulating insulin and serum testosterone as we…	Food compound	Preclinical	Emerging	0	—		PubChem
Flaxseed Natural product Human Study Flaxseed oil omega-3 supplementation for 12 weeks in women with PCOS ha… Human Study The beneficial effects of flaxseed supplementation on metabolic status…	Nutraceutical	Preclinical	Emerging	0	—		—
Testosterone Natural product Meta Analysis, Review This meta-analysis suggested that quercetin has positive effects on PCO… Meta Analysis, Review This meta-analysis suggests that consumption of tea supplementation in… Human Study An 8-week low-starch/low-dairy diet resulted in weight loss, improved i…	Food compound	Preclinical	Emerging	0	—		PubChem
Salvia Miltiorrhiza Natural product	Nutraceutical	Preclinical	Emerging	0	—		—
Myricetin Natural product	Food compound	Preclinical	Emerging	0	—		PubChem
Ginseng (Korean) Natural product	Nutraceutical	Preclinical	Emerging	0	—		—
Naringenin Natural product	Food compound	Preclinical	Emerging	0	—		PubChem
Buckwheat Natural product Human Study D-chiro-inositol has a therapeutic effect in lean women with the polycy… Human Study The compound found in buckwheat known as d-chiro-inositol have a therap…	Nutraceutical	Preclinical	Emerging	0	—		—
Spearmint Natural product Human Study Spearmint herbal tea has significant anti-androgen effects in polycysti…	Nutraceutical	Preclinical	Emerging	0	—		—
Dhea (Dehydroepiandrosterone) Natural product Human Study Adrenal androgen excess in the polycystic ovary syndrome patients is re… Human Study Magnesium supplementation resulted in reduced BMI and testosterone leve… Human Study Selenium supplementation for 8 weeks among PCOS women had beneficial ef…	Nutraceutical	Preclinical	Emerging	0	—		—

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.